BR112016028316A2 - composição farmacêutica oral de isotretinoina, seu processo de preparação e método de tratamento - Google Patents
composição farmacêutica oral de isotretinoina, seu processo de preparação e método de tratamentoInfo
- Publication number
- BR112016028316A2 BR112016028316A2 BR112016028316A BR112016028316A BR112016028316A2 BR 112016028316 A2 BR112016028316 A2 BR 112016028316A2 BR 112016028316 A BR112016028316 A BR 112016028316A BR 112016028316 A BR112016028316 A BR 112016028316A BR 112016028316 A2 BR112016028316 A2 BR 112016028316A2
- Authority
- BR
- Brazil
- Prior art keywords
- pharmaceutical composition
- isotretinoin
- preparation process
- treatment method
- oral pharmaceutical
- Prior art date
Links
- SHGAZHPCJJPHSC-NUEINMDLSA-N Isotretinoin Chemical group OC(=O)C=C(C)/C=C/C=C(C)C=CC1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-NUEINMDLSA-N 0.000 title abstract 2
- 229960005280 isotretinoin Drugs 0.000 title abstract 2
- 239000008203 oral pharmaceutical composition Substances 0.000 title abstract 2
- 238000000034 method Methods 0.000 title 1
- 238000002360 preparation method Methods 0.000 title 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/203—Retinoic acids ; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4833—Encapsulating processes; Filling of capsules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Dermatology (AREA)
- Nutrition Science (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Physiology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Pulmonology (AREA)
- Hematology (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN1456DE2014 | 2014-06-02 | ||
IN1737DE2014 | 2014-06-30 | ||
IN4002DE2014 | 2014-12-30 | ||
PCT/IB2015/054088 WO2015186039A1 (en) | 2014-06-02 | 2015-05-29 | Oral pharmaceutical composition of isotretinoin |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112016028316A2 true BR112016028316A2 (pt) | 2017-08-22 |
Family
ID=54766227
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112016028316A BR112016028316A2 (pt) | 2014-06-02 | 2015-05-29 | composição farmacêutica oral de isotretinoina, seu processo de preparação e método de tratamento |
Country Status (10)
Country | Link |
---|---|
US (2) | US20160081965A1 (pt) |
EP (1) | EP3148645A4 (pt) |
JP (1) | JP2017516794A (pt) |
AU (1) | AU2015270187A1 (pt) |
BR (1) | BR112016028316A2 (pt) |
CA (1) | CA2950533A1 (pt) |
MA (1) | MA40313A (pt) |
MX (1) | MX2016015464A (pt) |
RU (1) | RU2016150868A (pt) |
WO (1) | WO2015186039A1 (pt) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10933018B2 (en) | 2015-10-30 | 2021-03-02 | Timber Pharmaceuticals Llc | Isotretinoin formulations and uses and methods thereof |
US10517846B2 (en) | 2016-05-26 | 2019-12-31 | Dr. Reddy's Laboratories Ltd. | Pharmaceutical compositions for treating acne |
US10716774B1 (en) | 2018-01-05 | 2020-07-21 | Yale Pharmaceuticals LLC | Pharmaceutical compositions containing isotretinoin with improved dissolution profile and enhanced stability |
KR102065150B1 (ko) | 2018-04-27 | 2020-01-10 | (주)케어젠 | 이소트레티노인-펩타이드 결합체를 유효성분으로 포함하는 비만의 예방 또는 치료용 조성물 |
CN109100454B (zh) * | 2018-10-24 | 2021-08-06 | 中国日用化学研究院有限公司 | 一种同时测定表面活性剂产品中亚硫酸盐和硫酸盐含量的方法 |
WO2023108074A1 (en) * | 2021-12-08 | 2023-06-15 | Atai Life Sciences | Novel salvinorin compositions |
US12016830B2 (en) * | 2022-07-01 | 2024-06-25 | Acrotech Biopharma, LLC | Pharmaceutical compositions comprising isotretinoin and processes for preparation and uses thereof |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4545977A (en) * | 1985-01-11 | 1985-10-08 | G. D. Searle & Co. | Compositions and methods for treating severe acne with isotretinoin |
PE20001227A1 (es) * | 1998-10-30 | 2000-11-06 | Hoffmann La Roche | Procesos para producir una composicion de isotretinoina |
FR2807662A1 (fr) * | 2000-04-12 | 2001-10-19 | Cll Pharma | Procede pour stabiliser la granulometrie d'un principe actif verulent disperse dans un liquide et ses applications |
EP1318791B1 (en) * | 2000-09-22 | 2004-07-07 | Galephar M/F | Pharmaceutical semi-solid composition of isotretinoin |
EP1455730A4 (en) * | 2001-12-06 | 2006-01-18 | Ranbaxy Lab Ltd | NANOTEHOUS ISOTRETINOINE COMPOSITIONS |
JP2010510988A (ja) * | 2006-11-28 | 2010-04-08 | マリナス ファーマシューティカルズ | ナノ粒子製剤とその製造方法およびその利用 |
EP2370057A1 (en) * | 2008-12-31 | 2011-10-05 | Sunev Pharma Solution Limited Corporate | Topical herbal formulation for treatment of acne and skin disorders |
WO2010134047A2 (en) * | 2009-05-20 | 2010-11-25 | Ranbaxy Laboratories Limited | Liquid dosage forms of isotretinoin |
CA2836228A1 (en) * | 2012-12-13 | 2014-03-06 | Galephar Pharmaceutical Research, Inc. | Pharmaceutical semi-solid composition of isotretinoin |
-
2015
- 2015-05-29 CA CA2950533A patent/CA2950533A1/en not_active Abandoned
- 2015-05-29 EP EP15802494.3A patent/EP3148645A4/en not_active Withdrawn
- 2015-05-29 RU RU2016150868A patent/RU2016150868A/ru not_active Application Discontinuation
- 2015-05-29 WO PCT/IB2015/054088 patent/WO2015186039A1/en active Application Filing
- 2015-05-29 MA MA040313A patent/MA40313A/fr unknown
- 2015-05-29 MX MX2016015464A patent/MX2016015464A/es unknown
- 2015-05-29 AU AU2015270187A patent/AU2015270187A1/en not_active Abandoned
- 2015-05-29 JP JP2016569724A patent/JP2017516794A/ja not_active Withdrawn
- 2015-05-29 BR BR112016028316A patent/BR112016028316A2/pt not_active IP Right Cessation
- 2015-12-03 US US14/958,337 patent/US20160081965A1/en not_active Abandoned
-
2017
- 2017-08-02 US US15/666,704 patent/US20170326092A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
AU2015270187A1 (en) | 2016-12-15 |
CA2950533A1 (en) | 2015-12-10 |
EP3148645A1 (en) | 2017-04-05 |
RU2016150868A (ru) | 2018-07-17 |
MA40313A (fr) | 2017-04-05 |
RU2016150868A3 (pt) | 2019-01-15 |
WO2015186039A1 (en) | 2015-12-10 |
EP3148645A4 (en) | 2017-11-15 |
US20160081965A1 (en) | 2016-03-24 |
MX2016015464A (es) | 2017-03-27 |
JP2017516794A (ja) | 2017-06-22 |
US20170326092A1 (en) | 2017-11-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA201802657B (en) | Crystal forms of beta-nicotinamide mononucleotide | |
BR112016028316A2 (pt) | composição farmacêutica oral de isotretinoina, seu processo de preparação e método de tratamento | |
BR112017006779A2 (pt) | composição farmacêutica oral de baixa dose seu processo de preparação e método de tratamento | |
EP3153169A4 (en) | Method for treating tumour, pharmaceutical composition and medicine box kit | |
BR112017003346A2 (pt) | derivados de pirazolopiridina, seus usos, e composição farmacêutica | |
CO2017002472A2 (es) | Formulación de acetato de abiraterona | |
CL2016001587A1 (es) | Derivado basado en 1,2-naftoquinona y método de preparación del mismo. | |
BR112017018620A2 (pt) | método de administração de tradipitanto, e, tradipitanto. | |
CL2015001772A1 (es) | Composición farmacéutica para el tratamiento de dolor cabeza, y método de preparación de la misma. | |
CO2017003955A2 (es) | Compuestos de 1-alquil-6-oxo-1,6-dihidropiridin-3-ilo y usos de los mismos | |
BR112017003705A2 (pt) | compostos contendo nitrogênio tricíclicos para o tratamento de infecção por neisseria gonorrhoea | |
BR112016024421A2 (pt) | composição farmacêutica, cápsula e uso da composição farmacêutica | |
BR112015031417A8 (pt) | forma de dosagem farmacêutica, composição farmacêutica, métodos para tratamento de um paciente com necessidade de cisteamina e para preparo de uma forma de dosagem | |
BR112017000898A2 (pt) | oritavancina de alta pureza e método de produção da mesma | |
BR112017001221A2 (pt) | derivados de indolizina que são aplicáveis a doenças neurodegenerativas | |
BR112016024096A2 (pt) | novo bacteriófago e composição compreendendo o mesmo | |
BR112017025427A2 (pt) | composição farmacêutica oral | |
HK1245794A1 (zh) | 咪唑並噁嗪晶體、含有所述晶體的藥物組合物和製備所述晶體的方法 | |
BR112016028083A2 (pt) | Composição oral farmacêutica de isotretinoina e seu processo de preparação | |
BR112017004580A2 (pt) | composto, composição farmacêutica, produto de combinação, uso de um composto ou sal farmaceuticamente aceitável, e, método de tratamento. | |
BR112017014189A2 (pt) | terapia de câncer com um parvovirus combinado com bevacizumabe | |
BR112017008097A2 (pt) | método para tratar condições oculares | |
BR112017001963A2 (pt) | composição farmacêutica oral, seu processo de preparação e método de tratamento | |
BR112016020556A8 (pt) | compostos, composição farmacêutica, método de modulação da atividade do receptor de grelina, método para o tratamento de uma doença e usos de um composto | |
IN2014MU00916A (pt) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
B08F | Application fees: application dismissed [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 5A ANUIDADE. |
|
B07E | Notice of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2594 DE 24-09-2020 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |